Hybio Pharmaceutical's (SHE:300199) Pingshan Branch in China passed the U.S. Food and Drug Administration's inspection after no deficiencies requiring regulatory action were found, according to a Shenzhen bourse filing on Thursday.
The routine inspection was conducted between June 18 and June 26 in compliance with current good manufacturing practice (cGMP) requirements for drug manufacturing.
The Chinese pharmaceutical company's shares slipped 1% during the afternoon trade.